Literature DB >> 17111375

Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice.

Hongxin Dong1, Maureen V Martin, Shawn Chambers, John G Csernansky.   

Abstract

Although there is evidence that beta-amyloid impairs synaptic function, the relationship between beta-amyloid and synapse loss is not well understood. In this study we assessed synapse density within the hippocampus and the entorhinal cortex of Tg2576 mice at 6-18 months of age using stereological methods at both the light and electron microscope levels. Under light microscopy we failed to find overall decreases in the density of synaptophysin-positive boutons in any brain areas selected, but bouton density was significantly decreased within 200 mum of compact beta-amyloid plaques in the outer molecular layer of the dentate gyrus and Layers II and III of the entorhinal cortex at 15-18 months of age in Tg 2576 mice. Under electron microscopy, we found overall decreases in synapse density in the outer molecular layer of the dentate gyrus at both 6-9 and 15-18 months of age, and in Layers II and III of the entorhinal cortex at 15-18 months of age in Tg 2576 mice. However, we did not find overall changes in synapse density in the stratum radiatum of the CA1 subfield. Furthermore, in the two former brain areas we found a correlation between lower synapse density and greater proximity to beta-amyloid plaques. These results provide the first quantitative morphological evidence at the ultrastructure level of a spatial relationship between beta-amyloid plaques and synapse loss within the hippocampus and the entorhinal cortex of Tg2576 mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17111375      PMCID: PMC1661843          DOI: 10.1002/cne.21176

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  71 in total

1.  Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model.

Authors:  John F Reilly; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

2.  Academic highlights: emerging therapeutic strategies in Alzheimer's disease.

Authors:  George T Grossberg; Judy Corey-Bloom; Gary W Small; Pierre N Tariot
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

3.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 4.  Memantine.

Authors:  Blair Jarvis; David P Figgitt
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Int J Geriatr Psychiatry       Date:  2003-09       Impact factor: 3.485

6.  Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders.

Authors:  Paulo Roberto Louzada; Andréa C Paula Lima; Dayde L Mendonca-Silva; François Noël; Fernando G De Mello; Sérgio T Ferreira
Journal:  FASEB J       Date:  2004-03       Impact factor: 5.191

7.  BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.

Authors:  Masuo Ohno; Evgeny A Sametsky; Linda H Younkin; Holly Oakley; Steven G Younkin; Martin Citron; Robert Vassar; John F Disterhoft
Journal:  Neuron       Date:  2004-01-08       Impact factor: 17.173

8.  In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy.

Authors:  Megan E McLellan; Stephen T Kajdasz; Bradley T Hyman; Brian J Bacskai
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

Review 9.  Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.

Authors:  D M Walsh; I Klyubin; J V Fadeeva; M J Rowan; D J Selkoe
Journal:  Biochem Soc Trans       Date:  2002-08       Impact factor: 5.407

10.  Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype.

Authors:  T A Lanz; D B Carter; K M Merchant
Journal:  Neurobiol Dis       Date:  2003-08       Impact factor: 5.996

View more
  63 in total

1.  Cognitive decline is associated with reduced reelin expression in the entorhinal cortex of aged rats.

Authors:  Alexis M Stranahan; Rebecca P Haberman; Michela Gallagher
Journal:  Cereb Cortex       Date:  2010-06-10       Impact factor: 5.357

Review 2.  Episodic memory on the path to Alzheimer's disease.

Authors:  Michela Gallagher; Ming Teng Koh
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

3.  Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.

Authors:  Hongxin Dong; Keely M Murphy; Liping Meng; Janitza Montalvo-Ortiz; Ziling Zeng; Benedict J Kolber; Shanshan Zhang; Louis J Muglia; John G Csernansky
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology.

Authors:  Markus Morawski; Gert Brückner; Carsten Jäger; Gudrun Seeger; Russel T Matthews; Thomas Arendt
Journal:  Brain Pathol       Date:  2012-01-13       Impact factor: 6.508

5.  Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease.

Authors:  Mark E Bardgett; Natasha N Davis; Patrick J Schultheis; Molly S Griffith
Journal:  Neurobiol Learn Mem       Date:  2010-11-10       Impact factor: 2.877

Review 6.  Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.

Authors:  Houshang Amiri; Kolsoum Saeidi; Parvin Borhani; Arash Manafirad; Mahdi Ghavami; Valerio Zerbi
Journal:  ACS Chem Neurosci       Date:  2013-09-26       Impact factor: 4.418

Review 7.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

9.  Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease.

Authors:  Sylvia E Perez; Stephen Lumayag; Beatrix Kovacs; Elliott J Mufson; Shunbin Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-12       Impact factor: 4.799

10.  Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw.

Authors:  Joanne M Ajmo; Lauren A Bailey; Matthew D Howell; Lisa K Cortez; Keith R Pennypacker; Hina N Mehta; Dave Morgan; Marcia N Gordon; Paul E Gottschall
Journal:  J Neurochem       Date:  2010-02-17       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.